Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children.
about
Expanded CD34+ human umbilical cord blood cells generate multiple lymphohematopoietic lineages in NOD-scid IL2rgamma(null) miceHaploidentical Transplantation in Children with Acute Leukemia: The Unresolved IssuesRecent advances in haploidentical hematopoietic stem cell transplantation using ex vivo T cell-depleted graft in children and adolescentsAlternative donor transplant of benign primary hematologic disordersAdipose-derived stem cells: selecting for translational successAdvances in haplo-identical stem cell transplantation in adults with high-risk hematological malignanciesTransplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors.Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management.Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgeneEvaluation of bone marrow mononuclear cells as an adjunct therapy to minced muscle graft for the treatment of volumetric muscle loss injuries.Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.Side population cells in highly enriched CD34-positive cells from peripheral blood progenitor cells identify an immature subtype of hematopoietic progenitor cells but do not predict time to engraftment in patients treated with high-dose therapy.The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemiaCD6 as a therapeutic target in autoimmune diseases: successes and challenges.T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCTKIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL.Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies.Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells.Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials networMinimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia.Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantationEngineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMVEnhanced T-cell reconstitution by hematopoietic progenitors expanded ex vivo using the Notch ligand Delta1Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantationClinical strategies for expansion of haematopoietic stem cells.Use of natural killer cells in hematopoetic stem cell transplantation.Overview of T-cell depletion in haploidentical stem cell transplantation.Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell tMolecular defects in T- and B-cell primary immunodeficiency diseases.The Role of HLA in Cord Blood Transplantation.Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation.Risk assessment in haematopoietic stem cell transplantation: histocompatibility.Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States.Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303Myogenic-induced mesenchymal stem cells are capable of modulating the immune response by regulatory T cells.New strategies for haploidentical transplantation.Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation.T cell depletion in paediatric stem cell transplantation.The current role of T cell depletion in paediatric stem cell transplantation.Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation.
P2860
Q24657377-76FF4BE2-012B-4B00-B089-3F23B2E79F39Q26750671-C42A4812-870B-4FBD-B9C2-85C35586C103Q26750995-D238931B-A36E-4A2F-BAF2-AC7B5A79B4DBQ26823398-29CD8880-A26E-4601-B059-DD6B977E971DQ26824871-0FAE2C43-2633-4A2E-AE7C-B13F0D67B129Q27014857-36BC315A-04D8-4A72-A028-90A59887DCF8Q33358178-ABDDAD8C-CDCF-4BA1-A855-86C67CCECDE4Q33700953-4D111ABE-33E9-49FA-89C4-35FF530A83F8Q33781162-E877FF22-469C-4863-8469-571F7511E434Q33784964-72865609-4CFD-4A04-85B5-16B111ADA773Q33841389-C10354BD-0C5D-4D42-8123-D6B005DC9FA5Q33959785-52C769D5-2A4A-434B-BFD6-586FAA7AE784Q34057955-0620AA4C-EC78-4100-9F22-40750686C751Q34337963-9CD912B9-30F0-49B9-BC61-90088120CCA1Q34398411-BE7E1555-21DE-4C4C-85C1-A3726827B4FBQ34398420-3C48EC13-B3B9-413D-8F2F-B215F85F8190Q35083562-73532CE3-8BB6-4AB5-86C5-77F623974AEFQ35094029-433E1FEA-D308-4212-8E43-28DEA54A997EQ35148420-58615564-2268-44E0-A9E7-332DF00D480AQ35161219-08923567-87B1-4CE1-B253-0AF8DAEB7FCDQ35485612-B2B47CAD-288D-4FD9-A1A0-1CCB8927AE28Q35665033-65888475-1A8C-4E84-B9C5-EAC14F2516E6Q35751096-EE68A858-F4F8-45FA-8916-6F0096507A2BQ35824950-A0B1A10F-B9EF-420A-BF3B-ACAA3B4F526BQ35934167-6FA2EA53-5FF5-4C06-A4C2-1AAB9E3C4107Q36011664-D9309E72-24F0-432C-940D-9C3160A3C828Q36159937-6B578D5A-58A8-4E87-8A6C-6F8B23CFC2AEQ36212392-6E9EC799-C0FF-4027-8B6C-48950EA638FBQ36302334-1BBBAC05-527E-4713-BBBC-3D4F829F6FE7Q36336608-CE4D5836-C4B0-4B71-9AE4-8985D3A0BE92Q36795165-1B4E6CE7-9DDB-4570-A18D-7F08CFBD3F07Q36797744-556A16E3-569E-44AB-B502-912FAC88E145Q37051052-F799ED1B-4194-43F1-91F1-C57C6A1ED36CQ37145293-DF15F746-9F9E-4C6A-808D-D07D5690A9DCQ37591126-83D82B78-D1FA-4C4D-9CE5-49138ED0C312Q37978777-E4A0FE98-1E0F-4385-A0D1-1BBF89EEB19CQ38035452-6607E9DE-BDE5-44F1-B915-9B2CFF140089Q38097916-5E033714-AD98-4D64-B74B-640C6E112B5CQ38110308-A92A49EA-8457-42C7-8A8D-87662982DFB6Q38155240-645DFDB5-5B4C-4F2D-B8CB-3293B57A107A
P2860
Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Megadose transplantation of purified peripheral blood CD34
@nl
Megadose transplantation of pu ...... d parental donors in children.
@en
type
label
Megadose transplantation of purified peripheral blood CD34
@nl
Megadose transplantation of pu ...... d parental donors in children.
@en
prefLabel
Megadose transplantation of purified peripheral blood CD34
@nl
Megadose transplantation of pu ...... d parental donors in children.
@en
P2093
P2860
P356
P1476
Megadose transplantation of pu ...... d parental donors in children.
@en
P2093
Geiselhart A
Handgretinger R
Klingebiel T
Niethammer D
Schlegel PG
P2860
P2888
P304
P356
10.1038/SJ.BMT.1702996
P407
P577
2001-04-01T00:00:00Z
P6179
1044660749